Anti-parathyroid treatment effectiveness and persistence in incident haemodialysis patients with secondary hyperparathyroidism

Statistics

Original article

Efectividad y persistencia de los tratamientos del hiperparatiroidismo secundario en pacientes incidentes en hemodialisis

Angel Luis Martín de Franciscoa,

Corresponding author

angelmartindefrancisco@gmail.com

Corresponding author.

, Iain Andrew Gillespieb, Ioanna Gionic, Jürgen Floeged, Florian Kronenberge, Daniele Marcellif, David Collins. Wheelerg, Marc Froissarth, Tilman Bernhard. Druekei, on behalf of the ARO Steering Committee Cllaborators ◊

a Servicio de Nefrología, Hospital Universitario Valdecilla, Universidad de Cantabria, Santander, Spain

b Center for Observational Research (CfOR), Amgen Ltd, Uxbridge, United Kingdom

c On behalf of Amgen Ltd, United Kingdom

d Nephrology, RWTH University of Aachen, Aachen, Germany

e Division of Genetic Epidemiology, Department of Medical Genetics, Molecular and Clinical Pharmacology, Medical University of Innsbruck, Innsbruck, Austria

f EMEALA Medical Board, Fresenius Medical Care, Bad Homburg, Germany

g Center for Nephrology, Division of Medicine, University College London, United Kingdom

h International Development Nephrology, Amgen Europe GmbH, Zug, Switzerland

i Inserm U 1088, UFR Médecine/Pharmacie, Université de Picardie, Amiens, France

Read

9198

Times
was read the article

2513

Total PDF

6685

Total HTML

Share statistics

Article information

ISSN: 20132514
Original language: English

DOI:10.1016/j.nefroe.2016.02.007

The statistics are updated each day

Year/Month	Html	Pdf	Total

2025 6	8	2	10
2025 5	79	42	121
2025 4	60	33	93
2025 3	78	46	124
2025 2	77	39	116
2025 1	45	60	105
2024 12	44	31	75
2024 11	49	40	89
2024 10	42	35	77
2024 9	31	27	58
2024 8	62	63	125
2024 7	99	31	130
2024 6	46	37	83
2024 5	41	30	71
2024 4	76	28	104
2024 3	48	22	70
2024 2	38	29	67
2024 1	31	28	59
2023 12	22	15	37
2023 11	31	28	59
2023 10	55	23	78
2023 9	39	29	68
2023 8	35	23	58
2023 7	30	21	51
2023 6	46	13	59
2023 5	60	30	90
2023 4	22	15	37
2023 3	77	26	103
2023 2	39	16	55
2023 1	27	21	48
2022 12	72	32	104
2022 11	52	26	78
2022 10	89	38	127
2022 9	40	32	72
2022 8	61	54	115
2022 7	61	42	103
2022 6	34	27	61
2022 5	38	40	78
2022 4	28	40	68
2022 3	41	43	84
2022 2	36	35	71
2022 1	24	39	63
2021 12	41	38	79
2021 11	33	36	69
2021 10	33	36	69
2021 9	34	29	63
2021 8	34	36	70
2021 7	31	29	60
2021 6	64	19	83
2021 5	45	39	84
2021 4	83	35	118
2021 3	69	39	108
2021 2	51	16	67
2021 1	57	13	70
2020 12	27	14	41
2020 11	35	19	54
2020 10	31	23	54
2020 9	27	17	44
2020 8	45	7	52
2020 7	26	12	38
2020 6	35	11	46
2020 5	47	14	61
2020 4	32	20	52
2020 3	39	13	52
2020 2	117	24	141
2020 1	112	24	136
2019 12	106	17	123
2019 11	72	22	94
2019 10	31	12	43
2019 9	38	13	51
2019 8	18	14	32
2019 7	27	21	48
2019 6	23	28	51
2019 5	24	22	46
2019 4	52	30	82
2019 3	47	30	77
2019 2	23	12	35
2019 1	38	38	76
2018 12	182	43	225
2018 11	327	13	340
2018 10	162	16	178
2018 9	85	14	99
2018 8	45	16	61
2018 7	46	10	56
2018 6	58	12	70
2018 5	56	16	72
2018 4	141	4	145
2018 3	54	8	62
2018 2	45	6	51
2018 1	45	6	51
2017 12	48	9	57
2017 11	61	14	75
2017 10	31	7	38
2017 9	34	7	41
2017 8	29	4	33
2017 7	39	9	48
2017 6	43	6	49
2017 5	51	16	67
2017 4	43	8	51
2017 3	34	24	58
2017 2	62	23	85
2017 1	29	10	39
2016 12	51	9	60
2016 11	57	13	70
2016 10	166	13	179
2016 9	347	3	350
2016 8	247	4	251
2016 7	224	17	241
2016 6	130	0	130
2016 5	53	0	53

Show all

Indexed in:

Follow us:

Statistics

Indexed in:

Follow us:

Statistics

Subscribe to our newsletter